Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials
The study examined the effects of semaglutide on kidney function and safety in a large, broad type 2 diabetes population. eGFR and UACR were also analyzed by kidney function, albuminuria status, and kidney function. EGFR decreased from baseline to week 12 with all active treatments. The decline in e GFR was greater with semagLutide than with placebo.
